SRL Diagnostics launches fatty liver index for non-alcoholic fatty liver disease

SRL Diagnostics announced Tuesday the launch of “Fatty Liver Index”; a first-line diagnostic test for non-alcoholic fatty liver disease (NAFLD). According to the company’s press release, the Fatty Liver Index (FLI) is an algorithm-based index that includes multiple parameters; results of GGT (gamma-glutamyl-transferase) test, triglyceride (TG) test, weight, height, body mass index (BMI) and waist circumference for the prediction of fatty liver disease no alcoholic.

“Epidemiological studies suggest that the prevalence of NAFLD is around 9% to 32% of the general population in India, with higher prevalence among overweight or obese people and those with diabetes or pre-diabetes. Moreover, NAFLD has also become one of the leading causes of cirrhosis, hepatocellular carcinoma and liver transplant in India.India is the first country to add NAFLD to one of its national control programs diseases by integrating it into the National Cancer, Diabetes, Cardiovascular Disease and Stroke Prevention and Control Program of the Department of Health and Family Welfare Accurate diagnosis is the first step in controlling diseases. diseases and we are proud to lead this initiative for NAFLD,” Anand K, managing director of SRL Diagnostics, said in a statement.

“Fat liver disease is a common condition caused by the storage of extra fat in the liver. NAFLD becomes the most common chronic liver disease in the absence of low or no alcohol intake or any other obvious damaging factor. It is also associated with hyperlipidemia and cardiovascular disease. Fatty liver may have no symptoms. When symptoms appear, they may include abdominal pain and fatigue. Early diagnosis is important due to the absence of symptoms. The test is useful for those who are at high risk for NAFLD,” Dr. Kshama Pimpalgaonkar, Head of Department of Biochemistry, SRL Diagnostics, said on Tuesday.

“In some cases, NAFLD can progress to non-alcoholic steatohepatitis (NASH), marked by inflammation of the liver. Persistent inflammation of the liver will cause scarring (fibrosis), if the scarring extends (cirrhosis) it can lead to impaired liver function. Symptoms in such cases would be enlarged blood vessels just below the surface of the skin, enlarged spleen, red palms and yellowing of the skin and eyes (jaundice),” Dr Pimpalgaonkar added.

According to experts, NAFLD has a varied spectrum, the liver can progress to stages of fatty liver, fibrosis, cirrhosis, cancer (hepatocellular carcinoma) which can lead to death in early adulthood. Therefore, prediction of hepatic steatosis can help in better clinical management.

“It is an appropriate tool for the early intervention of metabolic disturbances. This can help with patient selection for ultrasound, intensive lifestyle counseling or liver biopsy. Patients who are overweight, diabetic, have elevated liver enzymes, or are suspected of having fatty liver disease are advised to get tested,” Diagnostic major added.

“Because NAFLD is a life-threatening disease, prevention and control efforts are needed at the individual level, the family level as well as the governmental and administrative level. SRL Diagnostics is proud to have released this important diagnostic tool to the public,” said.

Comments are closed.